Trial
NCT00485589
A Study of Ocrelizumab in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Are Naive to Methotrexate (FILM)
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Genentech, Inc.
Collaborators
Roche Pharma AG
Condition
Rheumatoid Arthritis
Intervention
Methotrexate
Why stopped
Based on analysis of results and consideration of available treatments, the overall benefit to risk profile of ocrelizumab was not favorable in RA.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-11-03